At 2.8% CAGR, Middle East & Africa Antibiotics & Antimycotics Market is Projected to be Worth US$ 2,187.95 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa antibiotics & antimycotics market was valued at US$ 1,756.67 million in 2023 and is expected to reach US$ 2,187.95 million by 2031, registering a CAGR of 2.8% from 2023 to 2031. Technological advancements in product development and treatment delivery approaches and increasing prevalence of infectious diseases are among the critical factors attributed to the Middle East & Africa antibiotics & antimycotics market expansion.

The pharmaceutical industry emphasizes incorporating intelligent technologies such as deep learning, artificial intelligence (AI), and machine learning in the development of new antibiotics. Researchers are working to establish tools and platforms for identifying new active compounds. Harnessing the capabilities of novel technologies in new antibiotic discoveries is expected to change the overall course of antibiotic and antimycotic development and approval processes.

Developing antibiotics for Gram-negative bacteria poses a significant challenge to researchers, and many drugs are still in the development phases. Limited permeability across the envelope of these bacteria due to nutrient-specific protein channels (porins) restricts the movement of non-essential molecules (including antibiotics) across membranes. Considering the difficulties around cell membrane permeability, researchers have developed a new Computational Antibiotic Screening Platform (CLASP) that helps identify potential drug molecules based on the analysis of porins. Advantages such as coarse grain (CG) resolution, advanced sampling techniques, and a parallel computing environment maximize the performance of CLASPs. The platform provides complete thermodynamic and kinetic results for potential drug molecules under study in a few hours. It also helps understand or identify small molecule libraries that yield structure-property relationships to discover antibiotics with high permeability.

There is a rising inclination toward precision medicine approaches that involve adjusting antibiotic treatments based on patients' genetic profiles and resistance patterns that are common among large populations. Such a revolution would improve drugs' functionality while ensuring minimal adverse effects and curbing the development of resistance. Phage therapy has emerged as another novel approach that involves a potential combination of traditional microbial treatments with bacteriophages to target and destroy antibiotic-resistant pathogens. Promising recent advancements in gene-editing technologies, such as CRISPR, has the ability to further enhance the prospects of phage therapy. Thus, technological advancements in drug development and treatment delivery approaches are expected to bring new growth trends in the antibiotics and antimycotics market growth in the coming years.

On the contrary, antimicrobial resistance, financial barriers, and extensive regulatory processes hamper the growth of Middle East & Africa antibiotics & antimycotics market.

Based on drug class, the Middle East & Africa antibiotics & antimycotics market is segmented into penicillin, cephalosporines, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. The penicillin segment held 42.8% share of the Middle East & Africa antibiotics & antimycotics market in 2023, amassing US$ 751.41 million. It is projected to garner US$ 940.95 million by 2031 to expand at 2.9% CAGR during 2023-2031.

Based on indication, the Middle East & Africa antibiotics & antimycotics market is segmented into skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others. The respiratory infections segment held 38.8% share of the Middle East & Africa antibiotics & antimycotics market in 2023, amassing US$ 681.96 million. It is projected to garner US$ 869.91 million by 2031 to expand at 3.1% CAGR during 2023-2031.

Based on route of administration, the Middle East & Africa antibiotics & antimycotics market is segmented into oral, topical, and others. The oral segment held 52.2% share of the Middle East & Africa antibiotics & antimycotics market in 2023, amassing US$ 916.62 million. It is projected to garner US$ 1,119.09 million by 2031 to expand at 2.5% CAGR during 2023-2031.

Based on distribution channel, the Middle East & Africa antibiotics & antimycotics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 56.4% share of the Middle East & Africa antibiotics & antimycotics market in 2023, amassing US$ 991.40 million. It is projected to garner US$ 1,204.13 million by 2031 to expand at 2.5% CAGR during 2023-2031.

Based on country, the Middle East & Africa antibiotics & antimycotics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia held 41.2% share of Middle East & Africa antibiotics & antimycotics market in 2023, amassing US$ 723.22 million. It is projected to garner US$ 911.28 million by 2031 to expand at 2.9% CAGR during 2023-2031.

Key players operating in the antibiotics & antimycotics market are Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com